Cytokinetics, Inc.

Smithkline Beecham Corporation

Glaxosmithkline LLC

Glaxosmithkline Intellectual Property (no.2) Limited

Cynthia A Parrish

Nicholas D Adams

Dashyant Dhanak

Xiangping Qian

Gustave Bergnes

Steven David Knight

Hong Jiang

Bradley Paul Morgan

David John Morgans, Jr

Luke W Ashcraft

Kevin J Duffy

Bing Yao

Jianchao Wang

Duke Fitch

Rosanna Tedesco

Han-Jie Zhou

Andrew I McDonald

Jennifer Kuo Chen Huang

Jonathan Michael Ghergurovich

Amita M Chaudhari

Domingos J Silva

Kenneth Wiggall

Christopher Joseph Aquino

Alexander Joseph Reif

Martha A Sarpong

Terence John Kiesow

Jerry Leroy Adams

Kenneth Allen Newlander

Jeffrey Michael Axten

Jun Tang

Michael Lee Moore

Yanhong Feng

Lance Howard Ridgers

Toshihiro Hamajima

Hongyi Lu

Jonathan M Ghergurovich

This invention relates to triazolones and triazolones for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of triazolones in the treatment of cancer.

Fatty acid synthase inhibitors

This invention relates to the use of triazolone derivatives for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of triazolones in the treatment of cancer.

Triazolones as fatty acid synthase inhibitors

This invention relates to spirocyclic piperidines according to Formula (I) and the use of spirocyclic piperidines for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of spirocyclic piperidines in the treatment of cancer. 

This invention relates to the use of triazolone derivatives of Formula (I) for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of triazolones in the treatment of cancer.

Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.

Imidazole-benzamide anti-cancer agents

Imidazopyridinyl benzamide mitotic kinesin inhibitors

Provided are compounds of Formula V and pharmaceutically acceptable salts thereof which may be useful for the treatment of cancer or other proliferative disorders. 

Imidazoyl-benzamide anti-cancer agents

Imidazopyridinyl-benzamide anti-cancer agents

Invented is a method of inhibiting the activity/function of PI3 kinases using quinoxaline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoxaline derivatives.

Quinoxaline derivatives as PI3 kinase inhibitors

Provided are compounds of Formula I and pharmaceutically acceptable salts thereof which may be useful for the treatment of cancer or other proliferative disorders. 

Provided herein are certain substituted N-phenethylbenzamide of formula V: that may be useful for treating certain cellular proliferation diseases and disorders by modulating the activity of CENP-E.

N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases

The present invention relates to a compound represented by Formula (I): and pharmaceutically acceptable salts. Compounds of the present invention inhibit Aurora kinase, making them especially suitable for the treatment of a number of diseases, including solid tumor cancers and hematological cancers.

Azaindole inhibitors of aurora kinases

Growing community of inventors

Philadelphia, PA, United States of America

Cynthia A Parrish